Drug intelligence / Profile preview

SII B.1.617.2

Development stage: Discontinued
Lead developer: Serum Institute of India
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SII B.1.617.2 is a monovalent COVID-19 vaccine candidate developed to target the SARS-CoV-2 Delta variant (lineage B.1.617.2). It was developed by Novavax and manufactured by Serum Institute of India (SII). The vaccine is based on recombinant protein subunit technology, using the spike protein of the Delta variant as its antigenic component, and formulated with Matrix-M adjuvant to enhance immune response[3][8][1]. Its primary indication was for prevention of COVID-19 caused by the Delta variant; however, development has been discontinued[1].

Other names: SII SARS-CoV-2 B.1.617.2SII Delta vaccine

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on SII B.1.617.2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SII B.1.617.2.

Explore the full profile